APA (7th ed.) Citation

Müller, V., Ruhnke, M., Hoffmann, O., Grafe, A., Tomé, O., Fett, W., . . . Schneeweiss, A. (2021). First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study. The breast, 60, . https://doi.org/10.1016/j.breast.2021.08.014

Chicago Style (17th ed.) Citation

Müller, Volkmar, Markus Ruhnke, Oliver Hoffmann, Andrea Grafe, Oliver Tomé, Werner Fett, Harald-Robert Bruch, Ann-Katrin Sommer-Joos, and Andreas Schneeweiss. "First-line Bevacizumab-containing Therapy for HER2-negative Locally Advanced/metastatic Breast Cancer: Real-world Experience from >2000 Patients Treated in the Multicentre AVANTI Study." The Breast 60 (2021). https://doi.org/10.1016/j.breast.2021.08.014.

MLA (9th ed.) Citation

Müller, Volkmar, et al. "First-line Bevacizumab-containing Therapy for HER2-negative Locally Advanced/metastatic Breast Cancer: Real-world Experience from >2000 Patients Treated in the Multicentre AVANTI Study." The Breast, vol. 60, 2021, https://doi.org/10.1016/j.breast.2021.08.014.